scholarly journals Septic cardiopathy: disputable issues and prospects

2020 ◽  
Vol 17 (2) ◽  
pp. 49-58
Author(s):  
I. A. Kozlov ◽  
I. N. Tyurin

The objective: to present current information about definitions, etiopathogenesis, clinical, laboratory and hemodynamic manifestations of septic cardiopathy, based on published data and the results of our own research.Results: septic cardiopathy is the most important pathogenetic component of sepsis, and cardiac dysfunction makes a significant contribution to its outcomes. It is found out that after staying in the intensive care unit for 3-4 days, the level of the inactive part of the precursor of the B-type natriuretic peptide (NT-proBNP) > 3,450 pg/ml indicates of the risk of death: area under ROC curve (AUC) 0.708 (p = 0.0041), sensitivity 63.6%, and specificity 66.7%. At the same time, NT-proBNP > 5,250 pg/ml is associated with the use of inotropic drugs: AUC 0.769 (p = 0.0007), sensitivity 76.9%, specificity 79.0%. The article describes the detection of septic cardiopathy using transpulmonary thermodilution and calculation of such indices as afterload-related cardiac performance and cardiac function index. Data on the age-related parameters of central hemodynamics and risk of pathological decrease in certain blood circulation indices characteristic of older patients are presented. The article discusses the feasibility of treating septic cardiopathy as a variant of acute heart failure, which can be manifested not only by a decreased systolic function (low left ventricular ejection fraction) but also by increased end-diastolic pressure in the ventricles (diastolic dysfunction) with a normal left ventricular ejection fraction. 

2020 ◽  
Vol 10 (3) ◽  
pp. 145-153 ◽  
Author(s):  
Francesco Lisi ◽  
Giuseppe Parisi ◽  
Margherita Ilaria Gioia ◽  
Luca Amato ◽  
Maria Consiglia Bellino ◽  
...  

Background: Hyperkalemia is one of the most frequent side effects related to renin-angiotensin-aldosterone system (RAAS) inhibition, and can influence optimization of heart failure (HF) therapy. Aim: To evaluate the occurrence of hyperkalemia in a series of outpatients with chronic HF and its relationship with RAAS inhibitor therapy. Method: We evaluated consecutive outpatients with HF and a reduced left ventricular ejection fraction. The incidence of hyperkalemia and consequent changes in RAAS inhibitor therapy were evaluated for each patient. Results: A history of hyperkalemia or at least 1 episode of hyperkalemia during follow-up was observed in 104 of 351 patients. Hyperkalemia mainly influenced mineralocorticoid receptor antagonist (MRA) therapy and, among patients with hyperkalemia, not taking MRA was associated with a greater risk of death on univariate analysis (HR = 6.39; 95% CI 2.76–14.79, p < 0.001) and multivariate analysis (HR = 5.24; 95% CI 1.87–14.72, p = 0.002) after correction for age, ischemic cardiomyopathy, diabetes, systolic arterial pressure, New York Heart Association class 3, left ventricular ejection fraction, presence of hyponatremia, glomerular filtration rate calculated by the EPI formula, and presence of N-terminal pro-B-type natriuretic peptide >1,000 pg/mL. Conclusion: The occurrence of hyperkalemia is common among outpatients with HF and it is the main cause of MRA withdrawal, which is associated with a worse prognosis. In this setting, the possibility of managing hyperkalemia using new classes of drugs could allow continuation of MRA therapy.


Sign in / Sign up

Export Citation Format

Share Document